Biopharmaceutical evaluation of ferrous salts in form of oral long-acting tablets. 1984

K Krzyśko, and W Bokowski, and L M Wichliński

We determined the relative bioavailability in men of two preparations containing ferrous salts in the form of long-action tablets in relation to analogous conventional preparations in the from of drops and tablets. The comparison of the bioavailability of preparations slowly and quickly releasing the active substance did not show any prolonged effect and greater absorption of drugs slowly releasing the active substance along the alimentary tract.

UI MeSH Term Description Entries
D007501 Iron A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN. Iron-56,Iron 56
D007700 Kinetics The rate dynamics in chemical or physical systems.
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D005296 Ferrous Compounds Inorganic or organic compounds that contain divalent iron. Compounds, Ferrous
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D013607 Tablets Solid dosage forms, of varying weight, size, and shape, which may be molded or compressed, and which contain a medicinal substance in pure or diluted form. (Dorland, 28th ed) Tablet

Related Publications

K Krzyśko, and W Bokowski, and L M Wichliński
January 1974, Farmatsiia,
K Krzyśko, and W Bokowski, and L M Wichliński
April 2010, Drug discoveries & therapeutics,
K Krzyśko, and W Bokowski, and L M Wichliński
March 1992, Drug and therapeutics bulletin,
K Krzyśko, and W Bokowski, and L M Wichliński
June 1960, Current therapeutic research, clinical and experimental,
K Krzyśko, and W Bokowski, and L M Wichliński
January 1973, Arzneimittel-Forschung,
K Krzyśko, and W Bokowski, and L M Wichliński
January 2005, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
K Krzyśko, and W Bokowski, and L M Wichliński
May 2009, Journal of pharmaceutical sciences,
K Krzyśko, and W Bokowski, and L M Wichliński
January 2005, La Clinica terapeutica,
K Krzyśko, and W Bokowski, and L M Wichliński
May 1985, Journal of pharmacobio-dynamics,
Copied contents to your clipboard!